Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy

Clinical and Experimental Hypertension

Volumn 38, Issue 1, 2016, Pages 10-22

  Akhtar, Md Sayeed ^a   Pillai, Krishna Kolappa ^a   Hassan, Quamrul ^a   Ansari, Shahid Husain ^a   Ali, Javed ^a   Akhtar, Mohammed ^a   Najmi, Abul Kalam ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Cardiomyopathy; diabetes; levosimendan; mitochondrial damage; oxidative damage; streptozotocin

Indexed keywords

C REACTIVE PROTEIN; CASPASE 3; CATALASE; CREATINE KINASE MB; GLUTATHIONE; INSULIN; LACTATE DEHYDROGENASE; LEVOSIMENDAN; MALONALDEHYDE; RAMIPRIL; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; GLUTATHIONE PEROXIDASE; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECG ABNORMALITY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FIBROSIS; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART RATE; HEMODYNAMICS; HYPERGLYCEMIA; MEAN ARTERIAL PRESSURE; MITOCHONDRIAL DEGENERATION; MUSCLE FIBRIL; NONHUMAN; OXIDATIVE STRESS; RAT; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; MALE; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CASPASE 3; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; GLUTATHIONE PEROXIDASE; HYDRAZONES; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PYRIDAZINES; RAMIPRIL; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954383818     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2015.1047947     Document Type: Article

References (47)

1. Interanational Diabetic Federation. (2011). One adult in ten will have diabetes by 2030. Available from: http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition [last accessed 24 Mar 2014]
2. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602
3. Levy D, Garrison RJ, Savage D, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
4. Iribarren C, Karter AJ, Go AS, et al. Glycaemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73
5. Tschope C, Walther T, Escher F, et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 2005; 19: 2057-9
6. +-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-71
7. +overload. J Physiol 2000; 527: 85-94
8. Chiu J, Farhangkhoee H, Ying BX, et al. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008; 45: 385-93
9. Klimas J, Kmecova J, Jankyova S, et al. Pycnogenol improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. Phytother Res 2010; 24: 969-74
10. + channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-59
11. Kaheinen P, Pollesello P, Levijoki J. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: 367-74
12. Erdei N, Papp Z, Pollesello P. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006; 148: 696-702
13. Delaney A, Bradford C, Caffrey JM, et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol 2010; 138: 281-9
14. Tasal A, Demir M, Kanadasi M. Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Med Sci Monit 2014; 20: 276-82
15. Packer M, Colucci W, Fisher L. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Fail 2012; 1: 103-11
16. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969; 22: 158-61
17. Young DS. Effects of drugs on clinical laboratory tests. Washington: American Association of Clinical Chemistry press; 1990
18. Lum G, Gambino SR. A comparison of serum versus heparinised plasma for routine chemistry tests. Am J Clin Pathol 1974; 61: 108-13
19. Lowry OH, Rosebrough NH, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75
20. Okhawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1970; 34: 30-8
21. Sedlak J, Lindsay RH. Estimation of total, protein bound, and nonprotein sulfhydryl groups in tissue with Ellmans reagent. Anal Biochem 1968; 25: 192-205
22. Marklund S, Marklund G. Involvement of superoxide anion radical in auto-oxidation by pyrogallol and a convenient assay of superoxide dismutase. Eur J Biochem 1974; 47: 469-74
23. Claiborne A. Catalase activity. In: Greenwald RA., ed. Handbook of methods for oxygen free radical research. Boca Raton, FL: CRC Press; 1985: 283-4
24. Lehmann GL, Carreras FI, Soria LR, et al. LPS induces the TNF-alpha-mediated downregulation of rat liver aquaporin-8: role in sepsis-associated cholestasi. Am J Physiol Gastrointest Liver Physiol 2008; 294: G567-G75
25. Eckersall PD. Recent advances and future prospects for the use of acute phase proteins and markers of disease in animals. Rev Med Vet 2000; 151: 577-84
26. Gurtu V, Kain SR, Zhang G. Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal Biochem 1997; 251: 98-102
27. Jensen RA, Acton EM, Peters JH. Doxorubicin cardiomyopathy in the rat: comparison of electrocardiogram, transmembrane potential and structural effects. J Cardiovasc Pharmacol 1984; 6: 186-200
28. Dabelea D, Bell RA, Agostino RB, et al. The writing group for the SEARCH for diabetes in youth study group: incidence of diabetes in youth in the United States. JAMA 2007; 297: 2716-24
29. Sotnikova R, Skalska S, Okruhlicova L, et al. Changes in the function and ultrastructure of vessels in the rat model of multiple low dose streptozotocin-induced diabetes. Gen Physiol Biophys 2006; 25: 289-302
30. Anjaneyulu M, Ramarao P. Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats. Methods Find Exp Clin Pharmacol 2003; 25: 205-8
31. 2+ in ventricular myocytes from diabetes resistant and susceptible rats. Mol Cell Biochem 2005; 269: 103-8
32. Fein FS, Strobeck JE, Malhotra A, et al. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981; 49: 1251-61
33. Chun-jun L, Lin L, Hui L, De-min Y. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 2012; 11: 73
34. Louhelainena M, Vahtolaa E, Forsten H, et al. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. J Hypertens 2009; 27: 2094-107
35. Biala A, Finckenberg P, Korpi A, et al. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive dahl/rapp rats. J Physiol Pharmacol 2011; 62: 275-85
36. Zhou H, Zhang L, Zheng M, et al. J. Improved myocardial function with supplement of levosimendan to celsior solution. Cardiovasc Pharmacol 2014; 64: 256-65
37. Aragno M, Mastrocola R, Alloatti G. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinol 2008; 149: 380-8
38. Gecit I, Kavak S, Yuksel MB, et al. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health 2014; 30: 47-51
39. Badole SL, Jangam GB, Chaudhari SM, et al. L-Glutamine supplementation prevents the development of experimental diabetic cardiomyopathy in streptozotocin-nicotinamide induced diabetic rats. PLoS One 2014; 9: e92697
40. Hoose LV, Sawers Y, Loganathan R, et al. Electrocardiographic changes with the onset of diabetes and the impact of aerobic exercise training in the Zucker Diabetic Fatty (ZDF) rat. Cariovasc Diabetol 2010; 9: 56
41. Li H, Liu Z, Wang J, et al. Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats. Cardiovasc Diabetol 2013; 12: 133-34
42. Lahtinen P, Pitkanen O, Polonen P, et al. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Crit Care Med 2011; 39: 2263-70
43. Azza B. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther 2010; 15: 175-81
44. Sharma AK, Srinivasan BP. Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci 2009; 38: 433-44
45. Nicklas JM, Gottlieb SS, Greenberg BH, et al. Levosimendan rapidly lowers plasma endothelin-1 and TNF-alpha levels in patients with severe heart failure. J Card Fail 1999; 5: 18
46. Thent ZC, Lin TS, Das S, Zakaria Z. Effect of Piper sarmentosum extract on the cardiovascular system of diabetic Sprague-Dawley rats: electron microscopic study. J Evid Based Complementary Altern Med 2012; 2012: 628750. doi: 10.1155/2012/628750
47. Yapici D, Altunkan Z, Ozeren M. Effects of levosimendan on myocardial ischaemia-reperfusion injury. Eur J Anaesthesiol 2008; 25: 8-14